Glycine transporters (GlyT1 and GlyT2), well known to regulate brain glycine levels, have been considered to be important therapeutic targets because their inhibition would increase brain glycine levels and NMDAR activity for brain disorders with limited NMDAR function such as schizophrenia. The gene discussed is SLC6A9; the disease is schizophrenia.